Cargando…

Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing

Inflammatory bowel diseases (IBDs) are characterized by chronic inflammatory disorders that are a result of an abnormal immune response mediated by a cytokine storm and immune cell infiltration. Proinflammatory cytokine therapeutic agents, represented by TNF inhibitors, have developed rapidly over r...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yijie, Yuan, Man, Xu, Yu, Xu, Hongxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502105/
https://www.ncbi.nlm.nih.gov/pubmed/36145301
http://dx.doi.org/10.3390/ph15091080
_version_ 1784795625491005440
author Song, Yijie
Yuan, Man
Xu, Yu
Xu, Hongxi
author_facet Song, Yijie
Yuan, Man
Xu, Yu
Xu, Hongxi
author_sort Song, Yijie
collection PubMed
description Inflammatory bowel diseases (IBDs) are characterized by chronic inflammatory disorders that are a result of an abnormal immune response mediated by a cytokine storm and immune cell infiltration. Proinflammatory cytokine therapeutic agents, represented by TNF inhibitors, have developed rapidly over recent years and are promising options for treating IBD. Antagonizing interleukins, interferons, and Janus kinases have demonstrated their respective advantages in clinical trials and are candidates for anti-TNF therapeutic failure. Furthermore, the blockade of lymphocyte homing contributes to the excessive immune response in colitis and ameliorates inflammation and tissue damage. Factors such as integrins, selectins, and chemokines jointly coordinate the accumulation of immune cells in inflammatory regions. This review assembles the major targets and agents currently targeting proinflammatory cytokines and lymphatic trafficking to facilitate subsequent drug development.
format Online
Article
Text
id pubmed-9502105
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95021052022-09-24 Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing Song, Yijie Yuan, Man Xu, Yu Xu, Hongxi Pharmaceuticals (Basel) Review Inflammatory bowel diseases (IBDs) are characterized by chronic inflammatory disorders that are a result of an abnormal immune response mediated by a cytokine storm and immune cell infiltration. Proinflammatory cytokine therapeutic agents, represented by TNF inhibitors, have developed rapidly over recent years and are promising options for treating IBD. Antagonizing interleukins, interferons, and Janus kinases have demonstrated their respective advantages in clinical trials and are candidates for anti-TNF therapeutic failure. Furthermore, the blockade of lymphocyte homing contributes to the excessive immune response in colitis and ameliorates inflammation and tissue damage. Factors such as integrins, selectins, and chemokines jointly coordinate the accumulation of immune cells in inflammatory regions. This review assembles the major targets and agents currently targeting proinflammatory cytokines and lymphatic trafficking to facilitate subsequent drug development. MDPI 2022-08-30 /pmc/articles/PMC9502105/ /pubmed/36145301 http://dx.doi.org/10.3390/ph15091080 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Song, Yijie
Yuan, Man
Xu, Yu
Xu, Hongxi
Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing
title Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing
title_full Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing
title_fullStr Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing
title_full_unstemmed Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing
title_short Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing
title_sort tackling inflammatory bowel diseases: targeting proinflammatory cytokines and lymphocyte homing
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502105/
https://www.ncbi.nlm.nih.gov/pubmed/36145301
http://dx.doi.org/10.3390/ph15091080
work_keys_str_mv AT songyijie tacklinginflammatoryboweldiseasestargetingproinflammatorycytokinesandlymphocytehoming
AT yuanman tacklinginflammatoryboweldiseasestargetingproinflammatorycytokinesandlymphocytehoming
AT xuyu tacklinginflammatoryboweldiseasestargetingproinflammatorycytokinesandlymphocytehoming
AT xuhongxi tacklinginflammatoryboweldiseasestargetingproinflammatorycytokinesandlymphocytehoming